Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Inventory: 2020-2025

Historic Change in Inventory for Eton Pharmaceuticals (ETON) over the last 5 years, with Sep 2025 value amounting to -$5.6 million.

  • Eton Pharmaceuticals' Change in Inventory fell 4218.46% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 528.86%. This contributed to the annual value of $1.3 million for FY2024, which is 270.06% up from last year.
  • Eton Pharmaceuticals' Change in Inventory amounted to -$5.6 million in Q3 2025, which was down 149.35% from $11.4 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Change in Inventory registered a high of $11.4 million during Q2 2025, and its lowest value of -$5.6 million during Q3 2025.
  • In the last 3 years, Eton Pharmaceuticals' Change in Inventory had a median value of -$120,000 in 2023 and averaged $632,636.
  • Over the last 5 years, Eton Pharmaceuticals' Change in Inventory had its largest YoY gain of 4,650.80% in 2025, and its largest YoY loss of 4,218.46% in 2025.
  • Eton Pharmaceuticals' Change in Inventory (Quarterly) stood at $216,000 in 2021, then slumped by 64.81% to $76,000 in 2022, then plummeted by 284.21% to -$140,000 in 2023, then skyrocketed by 302.14% to $283,000 in 2024, then crashed by 4,218.46% to -$5.6 million in 2025.
  • Its Change in Inventory stands at -$5.6 million for Q3 2025, versus $11.4 million for Q2 2025 and -$468,000 for Q1 2025.